{"id":"placebo-matching-with-sitagliptin","safety":{"commonSideEffects":[{"rate":"7-8","effect":"Nasopharyngitis"},{"rate":"5-6","effect":"Headache"},{"rate":"4-5","effect":"Upper respiratory tract infection"},{"rate":"1-2","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By prolonging the action of these incretin hormones, sitagliptin enhances glucose-dependent insulin secretion and reduces glucagon secretion, thereby lowering blood glucose levels in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning insulin is only stimulated when blood glucose is elevated, reducing hypoglycemia risk.","oneSentence":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase levels of incretin hormones, which stimulate insulin secretion in response to glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:33.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03101930","phase":"PHASE4","title":"Cardiovascular Effects of GLP-1 Receptor Activation","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-05-01","conditions":"Obesity, PreDiabetes","enrollment":329},{"nctId":"NCT01485614","phase":"PHASE3","title":"Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-10","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":200},{"nctId":"NCT00790205","phase":"PHASE3","title":"Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-10","conditions":"Type 2 Diabetes Mellitus","enrollment":14671},{"nctId":"NCT02917031","phase":"PHASE4","title":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-10","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":348},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT03646721","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-08-29","conditions":"Diabetes Mellitus, Type 2","enrollment":108},{"nctId":"NCT01619332","phase":"PHASE1, PHASE2","title":"Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Type II Diabetes","enrollment":220},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT01991197","phase":"PHASE2","title":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-04","conditions":"Psoriasis, Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02111096","phase":"PHASE2","title":"A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":174},{"nctId":"NCT00673894","phase":"NA","title":"Effects of Glutamine on GLP-1 and Insulin Secretion in Man","status":"COMPLETED","sponsor":"Garvan Institute of Medical Research","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":22},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02647320","phase":"PHASE2","title":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":298},{"nctId":"NCT02628392","phase":"NA","title":"A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-11","conditions":"Type2 Diabetes Mellitus","enrollment":368},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02226003","phase":"PHASE3","title":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01545388","phase":"PHASE3","title":"Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-23","conditions":"Type 2 Diabetes Mellitus","enrollment":337},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01590797","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT01552694","phase":"PHASE3","title":"Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-10","conditions":"Inflammation, Macrophage Infiltration, Cardiovascular Disease","enrollment":38},{"nctId":"NCT01488279","phase":"NA","title":"Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2012-09","conditions":"Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance","enrollment":10},{"nctId":"NCT01119846","phase":"PHASE2","title":"A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-05","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT02202161","phase":"PHASE2","title":"A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT01128621","phase":"PHASE2","title":"A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-23","conditions":"Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT01376323","phase":"PHASE2","title":"A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-13","conditions":"Diabetes Mellitus, Type 2","enrollment":92},{"nctId":"NCT01155284","phase":"PHASE2","title":"Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanford Health","startDate":"2010-08","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT00976261","phase":"PHASE1","title":"A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-17","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT01189890","phase":"PHASE3","title":"Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-08-16","conditions":"Type 2 Diabetes Mellitus","enrollment":480},{"nctId":"NCT01076088","phase":"PHASE3","title":"Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-15","conditions":"Type 2 Diabetes Mellitus","enrollment":744},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT00704132","phase":"PHASE1","title":"Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-14","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":57},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00730275","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-18","conditions":"Type 2 Diabetes","enrollment":35},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT00541229","phase":"PHASE1","title":"Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-24","conditions":"Type 2 Diabetes","enrollment":103},{"nctId":"NCT00305604","phase":"PHASE3","title":"Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03-08","conditions":"Type 2 Diabetes","enrollment":206},{"nctId":"NCT00103857","phase":"PHASE3","title":"MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03-17","conditions":"Type 2 Diabetes Mellitus","enrollment":1208},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT01260246","phase":"NA","title":"Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-12","conditions":"Type 2 Diabetes, Nonalcoholic Steatohepatitis","enrollment":12},{"nctId":"NCT01098539","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":507},{"nctId":"NCT01081834","phase":"PHASE3","title":"The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":678},{"nctId":"NCT00838903","phase":"PHASE3","title":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1049},{"nctId":"NCT00631488","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT00754988","phase":"PHASE3","title":"A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Diabetes Mellitus Type 2","enrollment":666},{"nctId":"NCT02949193","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":222},{"nctId":"NCT01859793","phase":"PHASE4","title":"Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2013-06","conditions":"Diabetes, Atherosclerosis","enrollment":38},{"nctId":"NCT00976937","phase":"PHASE3","title":"24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":319},{"nctId":"NCT00760344","phase":"PHASE2","title":"Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-03","conditions":"Diabetes Mellitus","enrollment":386},{"nctId":"NCT01549964","phase":"PHASE3","title":"Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-04","conditions":"Glycemic Control","enrollment":916},{"nctId":"NCT01829464","phase":"PHASE3","title":"TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-05","conditions":"Diabetes","enrollment":90},{"nctId":"NCT00337610","phase":"PHASE3","title":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":190},{"nctId":"NCT01414920","phase":"PHASE2","title":"Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 2","enrollment":368},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT01834274","phase":"PHASE3","title":"Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-06","conditions":"Diabetes Mellitus, Type 2","enrollment":96},{"nctId":"NCT00541775","phase":"PHASE3","title":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus","enrollment":273},{"nctId":"NCT00087516","phase":"PHASE3","title":"Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":741},{"nctId":"NCT00289848","phase":"PHASE3","title":"MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Type 2 Diabetes Mellitus","enrollment":530},{"nctId":"NCT01984606","phase":"PHASE3","title":"Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2015-01","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01289990","phase":"PHASE3","title":"Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":2705},{"nctId":"NCT00984867","phase":"PHASE3","title":"Dapagliflozin DPPIV Inhibitor add-on Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes","enrollment":833},{"nctId":"NCT00855166","phase":"PHASE3","title":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":182},{"nctId":"NCT01336738","phase":"PHASE2","title":"Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06","conditions":"Diabetes, Type 2","enrollment":266},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT00642278","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-04","conditions":"Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent","enrollment":451},{"nctId":"NCT01106690","phase":"PHASE3","title":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01602003","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":425}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching with Sitagliptin","genericName":"Placebo matching with Sitagliptin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase levels of incretin hormones, which stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}